L1Z1.F Alphatec Holdings Inc
- Market cap
- EUR 928M
- P/E
- -
- P/B
- 83.65x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is L1Z1.F undervalued?
Graham numberThe Graham number of Alphatec Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alphatec Holdings Inc fundamental analysis
No fundamental analysis for Alphatec Holdings Inc yet.
Alphatec Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alphatec Holdings Inc
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked po…
Full company profileAlphatec Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alphatec Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 120M | 102M | 91.7M | 113M | 145M | 243M | 351M | 482M | 612M | 764M | 836M |
| Gross Profit | 76.1M | 62.3M | 63.2M | 77.6M | 103M | 158M | 233M | 310M | 424M | 532M | 598M |
| Operating Income | -11.3M | -7.65M | -20.0M | -38.7M | -46.1M | -109M | -121M | -148M | -123M | -58.0M | -26.9M |
| EBITDA | - | 10.4M | -16.2M | -30.2M | -54.8M | -107M | -136M | -111M | -53.9M | -14.9M | 39.6M |
| Net Income | -29.9M | -2.29M | -29.0M | -57.0M | -79.0M | -144M | -152M | -187M | -162M | -143M | -86.9M |
| EPS | - | -0.12 | -0.67 | -0.93 | -0.96 | -1.45 | -1.43 | -1.37 | -1.12 | -0.97 | -0.57 |
| Balance Sheet | |||||||||||
| Total Assets | 94.2M | 84.7M | 129M | 170M | 261M | 572M | 513M | 805M | 776M | 791M | 797M |
| Total Liabilities | 136M | 111M | 112M | 126M | 131M | 493M | 550M | 727M | 790M | 779M | 799M |
| Shareholders' Equity | -41.5M | -26.7M | 17.6M | 43.6M | 130M | 79.4M | -36.7M | 78.1M | -14.2M | 12.4M | -2.30M |
| Cash & Short-term Investments | 19.6M | 22.5M | 29.1M | 47.1M | 108M | 187M | 84.7M | 221M | 139M | 161M | 79.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.96M | -8.73M | -25.6M | -33.1M | -46.4M | -73.4M | -75.1M | -78.5M | -44.7M | 45.2M | 54.2M |
| Capital Expenditure | 9.15M | 7.60M | 6.51M | 13.0M | 23.1M | 68.5M | 49.5M | 87.0M | 93.1M | 49.6M | 75.8M |
| Free Cash Flow | - | -16.3M | -32.5M | -46.2M | -70.3M | -142M | -133M | -165M | -138M | -4.41M | -21.5M |
| Ratios | |||||||||||
| ROE | - | - | -164.9% | -130.6% | -60.8% | -181.7% | - | -238.9% | - | -1,153.8% | - |
| ROA | -31.8% | -2.7% | -22.4% | -33.5% | -30.2% | -25.2% | -29.6% | -23.2% | -20.9% | -18.1% | -10.9% |
| Net Profit Margin | -24.9% | -2.3% | -31.6% | -50.3% | -54.5% | -59.3% | -43.4% | -38.7% | -26.5% | -18.8% | -10.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alphatec Holdings Inc dividends
Alphatec Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Aug 25, 2016.
Who owns Alphatec Holdings Inc
- Insiders 20.56%
- Institutions 75.11%
- Public & others 4.33%
- Shares outstanding 153M
- Free float 123M
Alphatec Holdings Inc company profile
- Company name
- Alphatec Holdings Inc
- Ticker
- L1Z1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 913
- Fiscal year end
- December
- Address
- 1950 Camino Vida Roble, Carlsbad, CA, United States, 92008
- Phone
- 760 431 9286
- Website
- atecspine.com
About Alphatec Holdings Inc
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
Alphatec Holdings Inc management
10- Mr. Patrick S. MilesChairman, CEO & President · born 1966
- Mr. J. Todd KoningExecutive VP & CFO · born 1973
- Mr. Scott LishChief Operating Officer · born 1981
- Mr. David P. SponselExecutive Vice President of Sales · born 1979
- Mr. Craig E. HunsakerExecutive Vice President of People & Culture · born 1964
- Mr. Robert JuddVP of Finance and Investor Relations & Controller
- Mr. Tyson Eliot MarshallGeneral Counsel & Corporate Secretary · born 1974
- Mr. Ali ShorooghiSenior Vice President of Marketing & Medical Education · born 1986
- Mr. Jonathan AllenExecutive Vice President of Commercial Operations · born 1960
- Dr. Luiz Pimenta M.D., Ph.D.Chief Medical Officer